Objective: This study aimed to collect preliminary evidence on the efficacy of milnacipran in reducing pain in women with provoked vestibulodynia (PVD) and to identify which patient characteristics predict treatment success.
Materials and Methods: A 12-week open-label trial was conducted in 22 women with PVD. The Pain Rating Index of the McGill Pain Questionnaire was the primary outcome measure. Other outcome measures included daily diaries, Beck Depression Inventory, State-Trait Anxiety Inventory, Female Sexual Function Index, Brief Pain Inventory, a personal or family history of fibromyalgia, and PVD subtype.
Results: Milnacipran (50–200 mg/d) significantly reduced pain severity on the Pain Rating Index (p = .001), coital pain (p = .001), tampon pain (p = .003), and mean vulvar pain (p ≤ .001). Scores were also decreased on the Beck Depression Inventory (p = .015), State-Trait Anxiety Inventory (p = .046), and Brief Pain Inventory (p = .019) and increased on the Female Sexual Function Index (p = .004). Fibromyalgia history, PVD subtype, presence of depression or anxiety, and level of impairment did not affect treatment response. By logistic regression analysis, it was noted that the odds of treatment success was 3 times higher among women who, at pretreatment, had a sexually satisfying relationship compared to those who did not (odds ratio = 3.30, confidence interval = 1.04–10.50, p = .043).
Conclusions: Milnacipran significantly reduced vestibular pain in women with PVD. Treatment success was predicted by pretreatment sexual satisfaction. A larger randomized controlled trial is necessary to confirm the efficacy of milnacipran in PVD and to identify other possible predictors of treatment outcome.
Milnacipran significantly reduced vestibular pain in women with provoked vestibulodynia, with pretreatment sexual satisfaction predicting treatment success.
1Department of Clinical Pharmacy, Obstetrics and Gynecology and Psychiatry, University of Tennessee Health Sciences Center, Memphis, TN; 2Department of Obstetrics, Gynecology and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ; 3Department of Obstetrics and Gynecology, School of Medicine and Dentistry, University of Rochester, Rochester, NY; 4Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN; 5Department of Obstetrics and Gynecology, Vanderbilt University, Nashville, TN; and 6Meharry Medical College, Nashville, TN
Dr. Brown received financial support from Forest Laboratories, Inc. for conducting the study. The remaining authors have no conflicts of interest to declare.
Reprint requests to: Candace Brown, PharmD, Department of Clinical Pharmacy, Pharmacy Bldg, Room 458, 881 Madison Ave, University of Tennessee Health Science Center, Memphis, TN 38163. E-mail: email@example.com.